Nilotinib leukaemia drug action

Référence de la vidéo 11930056
Nilotinib leukaemia drug binding to its target, the enzyme Bcr-Abl tyrosine kinase. This enzyme is produced by a genetic mutation, the swapping of parts of two chromosomes, leading to the formation of the oncogene (cancer-causing gene) Bcr-Abl, which produces a constantly-active version of normal Abl tyrosine kinase. This causes chronic myelogenous leukaemia (CML), a cancer of white blood cells. The drug Tasigna (Nilotinib) works by binding to the active site of the Bcr-Abl enzyme, producing a change in shape that prevents the enzyme from functioning. This causes the death of cancerous cells expressing the enzyme. Tasigna is marketed by Novartis.
Licence : Droits gérés
Crédit : Science Photo Library / Andrade, Ramon / 3dciencia
Model Release : Non requis
Property release : Non requis
Durée : 10 Secondes
Aspect ratio : 16/9
Restrictions : -

Prix pour cette vidéo À partir de 70 €

Publicité (Communication d'entreprise etc) À partir de 70 €
Rédactionnel (Sites web multiples etc) À partir de 125 €
Médias (Émission TV, Divertissement TV etc) À partir de 150 €

Mots-clés

;